Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis.

Transl Oncol · 2019 · PMC6484288 · PMID 31030101

Europe PMC DOI

hedged sentence

0.1300

closest p · 2.6× alpha

0.1300

boldest claim

The sentences

a slight trendP = .13not close (p > 0.1)

However, there was a slight trend of lower rates of T790M mutation in afatinib, with an HR of 4.77 [95% CI 0.63-36.31, P = .13] in the L858R mutation group for gefitinib ( Figure 4 B ).

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.